- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on ALK or ROS1-positive NSCLC
Total 35134 results
-
AstraZenecaDaiichi SankyoRecruitingAdvanced or Metastatic NSCLCUnited States, Taiwan, Italy, Spain, Poland, Japan, Belgium, Turkey, France, Korea, Republic of
-
AstraZenecaActive, not recruitingAdvanced or Metastatic NSCLCRussian Federation
-
Baodong QinUnknownNSCLC Stage IV | Anlotinib | EGFR T790M-negative | JS001China
-
Memorial Sloan Kettering Cancer CenterCompletedHER2-positive Carcinoma | HER2-positive Primary MalignancyUnited States
-
PfizerOxOnc Development LPCompletedNon Small Cell Lung Cancer | Crizotinib | ROS1 Proto OncogeneKorea, Republic of, China, Taiwan, Japan
-
iTeos Belgium SARecruitingMetastatic NSCLC | Stage III NSCLCUnited States, Belgium, Spain, Switzerland, Italy, France, Canada, Poland, Czechia
-
Mythic TherapeuticsRecruitingNon-Small Cell Lung Cancer | NSCLC | Advanced Non-Small Cell Lung Cancer | NSCLC Stage IV | NSCLC Stage IIIB | Advanced Non-Small Cell Squamous Lung Cancer | Advanced Non-Small Cell Non-Squamous Lung CancerUnited States, Australia, Korea, Republic of, United Kingdom
-
Astellas Pharma Global Development, Inc.WithdrawnSubjects With NSCLC With an EGFR Activating Mutation
-
The First Affiliated Hospital of Guangzhou Medical...UnknownPulmonary Metastases | NSCLCChina
-
Samsung Bioepis Co., Ltd.CompletedHER2 Positive Early or Locally Advanced Breast CancerCzechia
-
H. Lee Moffitt Cancer Center and Research InstituteNestle Health ScienceWithdrawnNSCLC | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | NSCLC Stage IIIB | Non-small Cell Lung Cancer Stage IIIB | NSCLC, Stage IIIA | Non-small Cell Lung Cancer Stage ⅢAUnited States
-
Żelazna Medical Centre, LLCFoundation for St. Sophia Specialist Hospital in WarsawRecruitingFetal Position and Presentation AbnormalitiesPoland
-
Japan Breast Cancer Research GroupChugai PharmaceuticalUnknownHER2-positive Locally Advanced or Metastatic Breast CancerJapan
-
Vestre Viken Hospital TrustOslo University Hospital; University Hospital of North Norway; Helse Stavanger... and other collaboratorsRecruitingOncology | NSCLC Stage IV | NSCLC, Stage IIINorway
-
Chinese University of Hong KongPamela Youde Nethersole Eastern HospitalCompleted
-
Shanghai Chest HospitalGeneplus-Beijing Co. Ltd.; Guangzhou Burning Rock Medical Examination Institute... and other collaboratorsUnknownNSCLC | Malignant HydrothoraxChina
-
University of BolognaUnknownVacuum Extraction; Failure, Affecting Fetus or Newborn | Persistent Occiput Posterior Position During Labor | Complication of DeliveryItaly
-
Hoffmann-La RocheRecruitingInoperable, Locally Advanced or Metastatic, ER-positive Breast CancerUnited States, Korea, Republic of, Spain, Australia, Israel
-
Centre Francois BaclesseHoffmann-La Roche; Groupe Francais De Pneumo-CancerologieTerminatedNSCLC Patients With EGFR Activating MutationFrance
-
National Taiwan University HospitalRecruiting
-
Maastricht University Medical CenterKU Leuven; University College, London; Erasmus Medical Center; Catholic University... and other collaboratorsRecruitingNSCLC Stage IV | Metastatic DiseaseBelgium, Netherlands, United Kingdom, France, Germany, Italy
-
Yonsei UniversityUnknownNon-small Cell Lung Cancer Harboring ROS1 RearrangementKorea, Republic of
-
AstraZenecaCompletedEGFR Mutation Status in aNSCLC Patients (Locally Advanced and/or Metastatic Disease) With Adenocarcinoma and Non-adenocarcinoma Histologies.Italy, Spain, United Kingdom, Sweden, Japan, Netherlands, Germany, France
-
UNICANCERARCAGY/ GINECO GROUP; SOLTI Breast Cancer Research GroupActive, not recruitingER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer | a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI StatusFrance
-
Massachusetts General HospitalNational Cancer Institute (NCI)CompletedNon-small Cell Lung Cancer Metastatic | Targetable Oncogenes (EGFR, ALK, ROS1)United States
-
University of California, IrvineWithdrawnAnesthetized Healthy Patients (ASA 1 or 2) in the Supine Position, Excluding Head, Neck and Head Surgeries | Anesthetized Patient With Severe Systemic Disease (ASA 3 or 4)United States
-
Henan Cancer HospitalUnknownAdvanced NSCLC With EGFR MutationChina
-
Nasser HannaGenentech, Inc.TerminatedNSCLC Stage IV | NSCLC, RecurrentUnited States
-
Shanghai Children's HospitalChildren's Hospital affiliated to Chongqing Medical University; Xuzhou maternal...Not yet recruitingPremature Infants | NICU Infants | Conventional NBS-positive Infants
-
AIPING ZHOUNot yet recruitingImmunotherapy | Sintilimab | Locally Advanced Solid Tumor | Oxaliplatin | HER2-positive | Gastric or Gastroesophageal Junction Adenocarcinoma | S-1China
-
Shanghai JMT-Bio Inc.Active, not recruitingLocal Advanced or Metastatic NSCLC | Harboring EGFR Common MutationChina
-
Fengxi SuUnknownBreast Cancer Patients in Premenopausal | Estrogen and/or Progesterone Receptor PositiveChina
-
Hoffmann-La RocheActive, not recruitingEstrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast CancerUnited States, Korea, Republic of, China, Poland, Taiwan, Turkey, United Kingdom, Australia, Argentina, Germany, Singapore, Thailand, Israel, Russian Federation, Ukraine, Brazil, South Africa
-
Hoffmann-La RocheActive, not recruitingEstrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast CancerUnited States, Italy, Korea, Republic of, Canada, Germany, United Kingdom, Australia, Belgium, Brazil, China, Denmark, France, Hong Kong, Portugal, Spain, Taiwan, Turkey, Japan, Argentina, Mexico, Israel, Poland, Russian Federation, Peru and more
-
National University Hospital, SingaporeUnknown
-
Seoul National University HospitalUnknownDurvalumab + Tremelimumab Combination Treatment, Pulmonary Sarcomatoid Carcinoma, NSCLCKorea, Republic of
-
Genentech, Inc.RecruitingEstrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast CancerKorea, Republic of, United States, Spain, Taiwan, United Kingdom, Japan, Germany, Argentina, Turkey, Greece, Italy, Singapore, South Africa
-
AmgenParexelWithdrawnMetastatic Non-small Cell Lung Cancer (NSCLC) | Non-squamous NSCLC
-
Seoul National University HospitalSeoul National University Bundang Hospital; SMG-SNU Boramae Medical CenterCompletedRelapsed or Refractory EBV-and CD30-positive LymphomasKorea, Republic of
-
AHS Cancer Control AlbertaEMD SeronoActive, not recruitingSquamous Cell Carcinoma of the Cervix | Cancer That is Associated With a Chronic Viral Infection | p16 Positive SCCHN | p16 Positive Squamous Cell Carcinoma of the Vagina or Vulva | p16 Positive Squamous Cell Carcinoma of the Penis | p16 Positive Squamous Cell Carcinoma of the Anus or Anal... and other conditionsCanada
-
GlaxoSmithKlineCompleted
-
ETOP IBCSG Partners FoundationRoche Pharma AGActive, not recruitingEGFRmutant Stage IIIB/C or IV Non-squamous NSCLCSingapore, Spain, Korea, Republic of, Switzerland, Germany
-
Jiangsu Province Nanjing Brain HospitalRecruiting
-
National Health Research Institutes, TaiwanTerminatedHead and Neck Cancer | NSCLCTaiwan
-
Xuanzhu Biopharmaceutical Co., Ltd.RecruitingROS1 Rearrangement Non-small Cell Lung Cancer | ALK Rearrangement Non-small Cell Lung CancerChina
-
Johns Hopkins UniversityNational Institutes of Health (NIH)CompletedHuman Immunodeficiency Virus Positive or NegativeUnited States
-
Biocon Biologics UK LtdNot yet recruitingHR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
-
Novartis PharmaceuticalsRecruitingALK Positive MalignanciesGermany, France, Australia, Belgium, Italy, Korea, Republic of, Poland, China, United States, Taiwan, Brazil, Bulgaria, Hong Kong, Japan, Lebanon, Malaysia, Spain, Russian Federation, Colombia, Singapore, Czechia
-
Jiangsu Province Nanjing Brain HospitalRecruiting
-
PfizerRecruitingNSCLC | IMT | ALCLChina, Taiwan, Japan, Russian Federation, Italy